Design, synthesis, and biological evaluation of novel potent and selective αvβ3/αvβ5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 926-934

  Marugán, Juan José ^a   Manthey, Carl ^a   Anaclerio, Beth ^a   Lafrance, Lou ^a   Lu, Tianbao ^a   Markotan, Tom ^a   Leonard, Kristi A ^a   Crysler, Carl ^a   Eisennagel, Stephen ^a   Dasgupta, Malini ^a   Tomczuk, Bruce ^a  

^a Development LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE; GUANIDINE DERIVATIVE; INDOLE DERIVATIVE; INTEGRIN INHIBITOR; NEW DRUG; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR INTEGRIN ALPHAVBETA5 INHIBITOR;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; CELL MEMBRANE PERMEABILITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MITSUNOBU REACTION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TIME TO REACH MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BENZOXAZOLES; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DRUG DESIGN; HUMANS; INDOLES; INTEGRIN ALPHAVBETA3; INTEGRINS; MICE; PERMEABILITY; RECEPTORS, VITRONECTIN; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 13944263529     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049725u     Document Type: Article

References (40)

1. Hynes, R. O. Integrins: Versatility, Modulation and Signaling in Cell Adhesion. Cell 1992, 69, 11-25.
2. M. J. Humphries, Integral Structure, Biochem. Soc. Trans. 2000, 28, 311-339.
3. (a) Iwao Ojima, Subrata Chakravarty and Qing Dong, Antithrombotic agents: From RGD to peptide mimetics, Bioorg. Med. Chem. 1995, 3, 337-360.
4. (b) Samanen, J, GPIIb/IIIa Antagonists. Annu. Rep. Med. Chem. 1996, 31, 91-100.
5. Elices, M. J. In Cell Adhesion Molecules and Matrix Proteins: Role in Health and Diseases; Mousa, S. A., Ed.; Springer and R. G. Landes Co.: Berlin, Germany, 1998; p 133.
6. 3. Science 2001, 294, 339-345.
7. 3 in Complex with an Arg-Gly-Asp Ligand. Science 2002, 296, 151-155.
8. 3. ChemBioChem 2002, 5, 470-473.
9. 3 Integrin. J. Med. Chem. 2002, 45, 5640-5648.
10. 5 integrin-dependent programmed cell death triggered by a peptide mimic of annexin V. Mol. Cell 2003, 11, 1151-1162.
11. 5 in patients with advanced solid tumours. Eur. J. Cancer 2003, 39, 917-926.
12. 5 in patients with advanced solid tumours. Eur. J. Cancer 2003, 39, 917-926.
13. (a) Duong, L. T.; Rodan, G. A. Regulation of osteoclast formation and function. Rev. Endocrinol. Metab. Dis. 2001, 2, 95-104.
14. 3 in osteoporosis see: Robey, P. G. Ann. Rep. Med. Chem. 1993, 28, 227.
15. 3 Integrin Inhibits Bone Resorption in Vitro and Prevents Osteoporosis in Vivo. J. Clin. Invest. 1997, 99, 2284-2292.
16. (a) Matsuno, H.; Stassen, J. M.; Vermylen, J.; Deckmyn, H. Inhibition of Integrin Function by a Cyclic RGD-Containing Peptide Prevents Neointima Formation. Circulation 1994, 90, 2203-2206.
17. 3 Integrin with a Small Peptide Antagonist GpenGRGDSPCA. J. Vasc. Surg. 1994, 19, 125-134.
18. Noiri, E.; Gailit, J.; Sheth, D.; Magazine, H.; Gurrath, M.; Müller, G.; Kessler, H.; Goligorsky, M. S. Cyclic RGD Peptides Ameliorate Ischemic Acute Renal Failure in Rats. Kidney Int. 1994, 46, 1050-1058.
19. (a) Hammes, H.-P.; Brownlee, M.; Jonczyk, A.; Sutter, A.; Preissner, K. T. Subcutaneous Injection of a Cyclic Peptide Antagonist of Vitronectin Receptor-Type Integrins Inhibits Retinal Neovascularization. Nat. Med. 1996, 2, 529.
20. 3 in Ocular Neovascular Diseases, Proc. Natl. Acad. Sci. U.S.A. 1986, 93, 9764.
21. 3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, Cell 1994, 79, 1157.
22. (b) Strömblad, S.; Cheresh, D. A. Integrins, angiogenesis and vascular cell survival. Chem. Biol. 1996, 3, 881-885.
23. 3 in Cell Adhesion, Motility, and Liver Metastasis of Murine RAW117 Large Cell Lymphoma. Cancer Res. 1996, 56, 3103-3111.
24. 3 (7E3 and LM609) Inhibit Sickle Red Blood Cell-Endothelium Interactions Induced by Platelet-Activating Factor. Blood 2000, 95, 368-374.
25. 3 Integrins. J. Med. Chem. 2002, 45, 1045-1051.
26. 3. Important Adv. Oncol. 1986, 69-87.
27. (a) Ahrens, Ingo; Peter, Karlheinz; Bode, Christoph. Use of GPIIb/IIIa Inhibitors in Cardiovascular Medicine. Expert Rev. Cardiovasc. Ther. 2003, 1, 233-242.
28. (b) Giavazzi, Raffaella; Nicoletti, Maria Ines. Small Molecules in Anti-Angiogenic Therapy. Curr. Opin. Invest. Drug 2002, 3, 482-491,
29. (c) Adams, S. P.; Lobb, R. R. Small-Molecule VLA-4 Antagonists, Prog. Respir. Res. 2001, 31, 302-305 (New Drugs for Asthma, Allergy and COPD).
30. v Integrin Antagonists: Novel Anticancer Agents. Expert Opin. Invest. Drugs 2000, 9, 1271-1279.
31. 3 Receptor Antagonists: Identification of Potent, Orally Active RGD Mimetics for the Treatment and Prevention of Osteoporosis. Abstracts of Papers, 226th ACS National Meeting, New York, United States, September 7-11, 2000.
32. 3) antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1483-1486.
33. 3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics. Bioorg. Med. Chem. Lett. 2002, 12, 2463-2465.
34. (d) Lark, M. W.; Stroup, G. B.; Hwang, S.-M.; James, I. E.; Rieman, D. J.; Drake, F. H.; Bradbeer, J. N.; Mathur, A.; Erhard, K. F.; Newlander, K. A.; Ross, S. T.; Salyers, K. L.; Smith, B. R.; Miller, W. H.; Huffman, W. F.; Gowen, M., Design and Characterization of Orally Active Arg-Gly-Asp Peptidomimetic Vitronectin Receptor Antagonist SB 265123 for Prevention of Bone Loss in Osteoporosis. J. Pharmacol. Exp. Ther. 1999, 291, 612-617.
35. (e) Keenan, R. M.; Miller, W. H.; Barton, L. S.; Bondinell, W. E.; Cousins, R. D.; Eppley, D. F.; Hwang, S.-M.; Kwon, C.; Lago, M. A.; Nguyen, T. T.; Smith, B. R.; Uzinskas, I. N.; Yuan, Catherine C. K. Orally Bioavailable Nonpeptide Vitronectin Receptor Antagonists Containing 2-Aminopyridine Arginine Mimetics. Bioorg. Med. Chem. Lett. 1999, 9, 1801-1806.
36. 3 Inhibitors. Proc. Am. Assoc. Cancer Res. 2001, 42, March 24-28, 368.
37. 3 Integrin Ligands. Bioorg. Med. Chem. Lett. 2004, 17, 4553-4555.
38. Davies, B.; Morris, T. Physiological Parameters in Laboratory Animals and Humans. Pharm. Res. 1993, 10, 1093-1095.
39. Dennis, M. S.; Carter, P.; Lazarus, R. A. Binding Interactions of Kistrin with Platelet Glycoprotein IIb-IIIa: Analysis by Site-Directed Mutagenesis. Proteins 1993, 15, 312-321.
40. Niiya, K.; Hudson, E.; Bader, R.; Byers-Ward, V.; Koziol, J. A.; Plow E. F.; Ruggeri, Z. M. Increased Surface Expression of the Membrane Glycoprotein IIb/IIIa Complex Induced by Platelet Activation. Relationship to the Binding of Fibrinogen and Platelet Aggregation. Blood 1987, 70, 475-483.